Population | Intention | Intervention | SoR | QoE | Ref. |
CPA patients with progressive | Control of infection | Micafungin 150 mg·day−1 | B | II | [16, 90, 97, |
disease, who fail, are intolerant | 98–100] | ||||
of or have triazole resistance | Amphotericin B deoxycholate 0.7–1.0 mg·kg−1·day−1 | C | III | [10] | |
Liposomal AmB 3 mg·kg−1·day−1 | B | IIa | [101] | ||
Caspofungin 50–70 mg·day−1 | C | IIa | [96, 102] |
SoR: strength of recommendation; QoE: quality of evidence.